Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaive patients with malignant pleural mesothelioma: Results of the International Expanded Access Program
Santoro, Armando × O'Brien, Mary E Stahel, Rolf A Nackaerts, Kristiaan Baas, Paul Karthaus, Meinolf Eberhardt, Wilfried Paz-Ares, Luis Sundstrom, Stein Liu, Yushan Ripoche, Veronique Blatter, Johannes Visseren-Grul, Carla M Manegold, Christian #
Lippincott Williams & Wilkins
Journal of Thoracic Oncology vol:3 issue:7 pages:756-763
Introduction: Previously published results from a randomized phase III study of pemetrexed plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a significant survival benefit and higher response rate compared with cisplatin. Although pernetrexed was under review by regulatory agencies, an International Expanded Access Program (EAP) provided more than 3000 mesothelioma patients with access to single-agent pemetrexed or pernetrexed in combination with cisplatin or carboplatin in 13 countries. This manuscript reports the safety and efficacy data from the nonrandomized open-label study in chemonaive patients receiving pernetrexed plus platinum under the EAP.